NCT00000303已完成2 期
Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Cocaine use
研究概览
简要总结
The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, baclofen is tested.
详细描述
16-week participation plus a 2 week lead in period. Participants are assigned randomly to placebo or baclofen. Participant attend group meetings 3 x/week.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •M/F ages 18-
- •cocaine dependence according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.
排除标准
- •Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or nursing women, dependence on ethanol (ETOH) or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
结局指标
主要结局
Cocaine use
Cocaine craving
Psychosocial progress
Retention
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4Cocaine-Related DisordersNCT00000301University of California, Los Angeles
已完成
2 期
Early Phase II Trials for Cocaine Medication Development - 1Cocaine-Related DisordersSubstance-Related DisordersNCT00000317New York State Psychiatric Institute31
已完成
2 期
Cognitive Remediation for Cocaine DependenceCocaine DependenceNCT01393457The University of Texas Health Science Center, Houston119
已完成
1 期
Pharmacokinetic Drug-drug Interaction of CKD-330 and D086HyperlipidemiasHypertensionNCT03017950Chong Kun Dang Pharmaceutical83
已完成
1 期
A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male ParticipantsHealthyNCT01732237Janssen-Cilag International NV18